15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Enanta Pharmaceuticals Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $12.00 to $28.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $20.40 sits 62% above the current $12.61. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.63 next quarter toward $-2.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Enanta Pharmaceuticals Inc.
As of Jul, 6 of 6 firms rate ENTA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ENTA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.63
Range $-0.95 – $-0.30 · 5 analysts · -28% YoY
Next period, 5 analysts expect Enanta Pharmaceuticals Inc to earn $-0.63 a share (range $-0.95 – $-0.30), versus $-0.87 a year earlier. Full-year consensus is $-1.88, growing to $-2.05 the year after.
REVENUE · NEXT QUARTER
$17.1M
Range $13.7M – $20.0M · 5 analysts · +13% YoY
Revenue is expected to reach $17.1M (range $13.7M – $20.0M), +12.9% year-over-year. Full-year consensus is $66.3M, rising to $66.6M next year.
Top analysts covering Enanta Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENTA.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$17.00+34.8% to target
Overall win rate
46%
+ Follow
#2
Ed Arce
HC Wainwright & Co. · Rank #107
Buy
$18.00+42.7% to target
Overall win rate
44%
+ Follow
#3
Roy Buchanan
JMP Securities · Rank #109
Buy
$25.00+98.3% to target
Overall win rate
48%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co.
Buy
$20.00+58.6% to target
Coverage
—
+ Follow
#5
EA
Ed Arce
WestPark Capital
Buy
$28.00+122.0% to target
Coverage
—
+ Follow
ENTA stock forecast FAQ
What is ENTA's average 12-month price target?+
The 5 analysts with a live target average $20.40 for Enanta Pharmaceuticals Inc over the next 12 months, ranging from a $28.00 high to a $12.00 low.
Is ENTA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ENTA?+
The Street-high target is $28.00 (WestPark Capital), and the Street-low is $12.00 (Evercore ISI Group). The average of all 5 active targets is $20.40.
How many Wall Street analysts cover ENTA?+
6 analysts have an active rating on Enanta Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering ENTA?+
Among analysts who currently cover ENTA, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $17.00 target.
What is Enanta Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.63 per share (range $-0.95 – $-0.30) across 5 analysts. Full-year EPS is projected at $-1.88, rising to $-2.05 the following year.
How much revenue is Enanta Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $17.1M (range $13.7M – $20.0M). Full-year revenue is projected at $66.3M, growing to $66.6M next year.
Have analysts been upgrading or downgrading ENTA lately?+
As of Jul, 6 of 6 firms rate ENTA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENTA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
